Safety, Pharmacokinetics (PK) and Tolerability Study of a Novel Drug for Treatment of Bacterial Infections

Inclusion Criteria: * Young healthy males, 18-45 years (inclusive) of age * Healthy as judged by a responsible physician with no clinically significant abnormality * Surgically sterile OR agrees to abstain from sexual intercourse with a female partner OR agrees to use a condom and spermicide during sexual intercourse with a female partner who uses another form of contraception * Body weight above 50 kg (Body Mass Index between 19 and 30 kg/m2) * Non-smokers * Willing and able to comply with study instructions and commit to all follow-up visits * Ability to understand, agree to and sign the study Informed Consent Form (ICF) Exclusion Criteria: * History of serious adverse reactions or hypersensitivity to any drug; or who have a known allergy to any of the test product(s) or any components in the test product(s); or history of hypersensitivity or allergic reactions to any of the study preparations as described in the Investigator's Brochure * Any clinically significant central nervous system, cardiac, pulmonary, metabolic, renal, hepatic or gastrointestinal conditions * Abnormal physical findings of clinical significance at the screening examination or baseline * History of orthostatic hypotension * Clinically significant abnormal laboratory values * Presence or history of allergies requiring acute or chronic treatment * 12 lead ECG abnormalities * Major surgical interventions within 6 months of the study * Has a positive pre-study Hepatitis B surface antigen; positive hepatitis C (HCV) antibody or detectable HCV ribonucleic acid (RNA); or positive HIV antibody result * Use of prescription or non-prescription drugs * Has a history of regular alcohol consumption * Loss of 500 mL blood or more during the 3 month period before the study * People that follow vegetarian or vegan diet * Symptoms of a significant somatic or mental illness in the four week period preceding drug administration * History of drug abuse or dependence within 12 months of the study * The subject has a positive pre-study alcohol or urine drug screen * Concurrent participation in another drug or device research study or within 60 days of post participation in another drug or device study * Considered by the Investigator to be unsuitable candidate for this study